We performed an in vivo study to increase clinical significance and successfully demonstrated that PARP1 inhibitor rucaparib, the FDA-approved chemotherapeutic drug for ovarian cancer, significantly decreased the degree of fibrosis in patient-derived keloid xenograft model. This evidence concerns the gene PARP1 and ovarian carcinoma.